Bernard F Morrey*

doi:10.19080/OROAJ.2018.05.555825

Review Article

A New Safe and Effective Treatment for Chronic Refractory Tendinopathy

Bernard F Morrey*

Orthopedic Department, Mayo Clinic, USA

Submission: April 20, 2018;Published: May 25, 2018

*Corresponding author: Bernard F Morrey, Orthopedic Department, Mayo Clinic, 200 First St SW, Rochester MN 55905, USA; Tel: 507-284-8314; Fax: 507-284-8935; Email: morrey.bernard@mayo.edu

How to cite this article: Bernard F Morrey. A New Safe and Effective Treatment for Chronic Refractory Tendinopathy. Ortho & Rheum Open Access J. 2018; 11(5): 555825. DOI: 10.19080/OROAJ.2018.11.555825.

Abstract

Chronic refractory tendinopathy accounts for over 30 million office visit per year (2013). In spite of the considerable burden of disease this condition represents, there remains no consensus regarding treatment, or even what constitutes the chronic refractory state. Recent studies have clarified the definition of a chronic refractory process. More importantly an innovative new technology appears to offer potential solution at all anatomic sites of involvement for the majority of patients. In the last 6 years, the use of an ultrasonic device directed to the pathologic tissue under ultrasound image guidance has proven extremely safe and effective in over 70,000 treatments. As clinical studies emerge documented experience suggests this treatment is performed with the difficulty and safety of a cortisone injection but with the same benefit of surgery without the cost or morbidity.

Keywords: Chronic refractory tendinopathy; Elbow; Lateral epicondylitis; Ultrasound percutaneous tenotomy

Introduction

A recent study from the Mayo Clinic documented the here to fore unknown fact that symptoms of lateral epicondylitis persist for 6 months in about 20% of patients with this problem [1]. Further, in that cohort of the 20% of patients still experiencing continued pain, the mean time to resolution was an additional 24 months (Figure 1). These observations prompted the investigators to define chronic refractory epicondylitis as a condition persisting for more than 6 months despite appropriate treatment. Furthermore, a review of the ICD codes employed in 2013 in the United States included over 30 million with a diagnosis of chronic tendinopathy or fasciitis. While the burden of the disease is considerable, there is wide divergence in the literature regarding the optimum treatment of the chronic refractory condition.

Since 2012 a novel approach to address this condition in the form of a percutaneous ultrasonic treatment was introduced. While ultrasonic or extracorporeal based treatment platforms have been employed in the past, wide spread acceptance has been limited due to the cost, discomfort unpredictable outcomes, complications and prolonged period of recovery. The phenomenal success of ultrasonic treatment for cataracts for over 20 years served as the stimulus to consider the same approach for another degenerative condition, tendinopathy [2]. The key features of this technology relate both to the device and to the technique

Device

Ultrasonic energy is delivered through a hollow probe the size of an 18 gauge needle. The probe is hollow allowing suction to be applied which removes the tissue cut by the ultrasonic energy. A third essential element is continuous irrigation through a sleeve that surrounds the probe (Figure 2). The specific intensity of the energy has been observed to remove degenerative tissue but to have little effect on normal tendon (Figure 3).

Materials and Methods/Technique

The specific technique has been described in detail for the tennis elbow [3] and patellar tendinopathy [4]. The first step is to confirm the diagnosis is consistent with the clinical presentation. Next is the identification of the characteristic ultrasonic signal changes associated with tendinopathy [5]. Hypoechoic changes at the site of attachment of the involved tendon, or thickening (>4mm) at the site of attachment of the plantar fascia at the medial tubercle of the calcaneus (Figure 4). Once the diagnosis is confirmed and the patient affirms desire to be treated, the involved area is sterilely prepared and isolated with sterile towels. The ultrasonic sensor is placed in a sterile sheaf and the area is anesthetized with a fast acting local anesthetic. An eleven blade makes a limited stab incision through skin and into the fascia, and the sterile, disposable hand piece is inserted to the site of pathology under ultrasonic guidance (Figures 5a & 5b). Treatment with the ultrasonic energy, delivered by depressing a peddle varies from 60-90secs to 3-5 minutes for more difficult and extensive conditions. When a classic hypoechoic lesion is present, the diseased tendon undergoes an immediate change in signal appearing normoechoic. If this occurs the area has been adequately treated. The highlights of this procedure are shown in Table 1.

Aftercare although there is one randomized controlled study underway (Hall, personal communication) to date there are little data to direct the optimum post-procedure management. The most common approach is to recommend strict rest for 2-3 days; 3 weeks of limited, sedentary activity; 3-6 weeks of gradually resumption of normal activities; if symptoms are resolving, we allow activity as tolerated. We do not feel additional adjunctive treatment is necessary. However, for plantar fasciitis we do advise continued of a walking boot for a week or two if the patient has been using this before the procedure. The general post procedure guidelines are shown in Table 2.

Results

A growing body of literature has consistently reported a safe, well tolerated procedure with a high degree of success. An animal model study demonstrated the effect of treating the degenerated tendon is for a return of Type 1 and 3 collagens return to normal concentrations and ratios at three weeks [6] (Figure 6). This suggests the mechanism of cutting and removing the degenerated tendon has a stimulatory effect on the healing process, postulated to be facilitated by the absence of diseased tissue that has not resorbed.

Several technique reports have appeared and the optimum treatment characteristics are becoming better established [3,4]. The initial clinical report appearing in the peer reviewed literature was in 2013 by Koh et al. [7]. These investigators report a prospective study of 20 patients so treated and documented 19 of were pain free at one year. Importantly, they reassessed this cohort and reported all 20 to be pain free at 3 years [8]. Of particular note is all 20 also had serial ultrasonic examinations of the elbow and the progression to improve or even healed tendon was documented in each patient. This cohort of patients has also been carefully followed by US examinations at discrete intervals for the 3 year period. This assessment has revealed 14 of the 20 appeared completely normal when later examined by ultrasound imaging [8]. Similarly a prospective study from the Mayo clinic reported 12 lateral and 7 medial epicondylitis patients. At one year 17 or the 19(88%) exhibited a satisfactory outcome [9]. Of interest, similar results have been documented at other sites of involvement: the knee (88%); [4] Achilles insertion (88%) [10]; plantar fasciitis (94% - 100%) [11] and hamstring insertionopathy at the pelvis [12]. With the introduction of the longer TX2 probe calcific tendonitis of the shoulder and gluteus tendinopathy are also being successfully treated. Of further interest is the documentation of successful salvage of failed open surgical intervention with this procedure [11,13].

Finally, Patel has also employed the procedure for plantar fibroma and reported no recurrences in 10 patients after one year of treatment [14]. Hence the technique appears to effectively remove scar tissue without recurrence in the short term.

Complications

After over 70,000 procedures through the first part of 2018, there have been 14 reported complications requiring additional treatment (Table 3). The presence of these problems did not prevent the outcome from being favorable in 10 of the 14.

Discussion

Since introduction, there has been a rapid adoption and acceptance of the procedure [15-17]. Recent reviews on the topic of chronic tendinopathy have not only recognized the efficacy of this approach, but even declared it is the ‘treatment of choice’ for this condition [18]. As the clinical experience evolves we will find more failures [19]. But further experience will better define the sensitivity of the results to selection; technique; preoperative issues such as steroid injections, worker’s compensation, and prior surgery; and post procedure treatment, including the need and value of adjunctive therapy, walking boot and the like.

The Future

As noted In September, 2015 a longer probe was introduced that allows for the treatment of calcific tendinopathy of the shoulder with the perception of markedly less recovery morbidity when compared to alternative treatment options. This device is also being widely used for gluteal tendinopathy with early clinical impression that this may be one of the most effective applications of the technology. Additional applications are being explored. Over 30 academic institutions are using this procedure in the United States and it is hoped additional prospective studies will be forth coming in the near future.

Author’s Experience

The author has treated over 475 patients since 2012. This experience parallels that of the literature with the elbow and the plantar fasciitis patients being most reliably improved (>90%). However all treatment sites have had a similar overall success rate. There have been no complications requiring a physician’s attention as yet in our practice. There have been 10 repeat procedures, 7 were overt failures while 3 represented extension of the initial pathology. The author has not performed an open or arthroscopic procedure for chronic tendinopathy since beginning to use this procedure.

Conclusion

The appropriate patient for definitive intervention is that patient with symptoms for six months or longer in spite of other treatment. This treatment option provides definitive treatment with the complexity of a steroid injection and with the effectiveness of surgery without the cost or morbidity. This degree of effectiveness coupled with the safety profile suggests this may well be the treatment platform of the future for this condition.

Conflict of Interest

Dr. Morrey is the medical director of Tenex Health.

IJCSMB.MS.ID.555825

Our Media Partner

OROAJ Menu

Useful Links

Downloads